We conducted a study to determine the p rognostic reliability ofpreoperative computerized dynam ic postu rography (CD?) in patients underg oing surgical excision of an acoustic neuroma. Our goal was to determine the correlation between objective preoperative assessments ofbalance fun ction and subjective postoperative pat ient self-assessments. To that end, we retrospectively reviewed the records of 21 adults who had unde/g one preoperative CD?, and we subsequently obtained their subjective assessments of balance fun ction byfollow-up telephone surveys at least 1y ear postoperatively. We conclude that although CD? has proven to be useful in many aspec ts ofbalance evaluation. it did not appeal' to be a valuable predictor of subjective postoperative balancefunction in these pat ients.
A central aspect of the COP protocol is the sen sory organi zation test (SOT), which is the focu s of much current research. The SOT helps the phy sician evaluate how visual , somatosensory, and vestibular inputs affect a pat ient's ability to maintain functional balance. This objective test measures the extent of a pati ent 's sway while standing on a force platfo rm during six conditions:
• Condition I is a simulation ofa common, normal state. With eyes open , the patient stands on a fixed platform amid a fixed visual surround. • In condition 2, the platform and visu al surround are both still fixed , but the patient's eyes are shut. • In condition 3, the eyes are open and the platform is fixed , but the visual surround tilts in the direction of the patient's sway, thereby delivering inaccurate visual information about ori entation 111 space. • Cond itions 4, 5, and 6 are the same as conditions I , 2, and 3, respectively, except that the platform moves. The sway-referenced platform tilts with the pati ent's sway, thereby altering somatosensory input. As a result, conditions 5 and 6 effect ively force a patient to rely on vestibular input s alone to maintain balance .
In th is article , we describe our study ofthe reliabil ity of preoperative COP as a prognostic indicator of post operative balance functi on in patients with acoustic neuroma. We chose subjective patient self-reports of postoperative balance function as an outcome mea sure because this information represents a direct assessment of how patients fee l about an issue that is ofprimary interest to them durin g preoperative counseling.
Patients and methods
Twenty-one patients-8 men and 13 women , aged 30 to PREOP ERATIVE COM PUTERIZED DYNAMIC PO STUROG RAPH Y AS A PRO G NO STIC IND ICATOR OF BALA NCE FUNCTION IN PATIENTS WI TH ACO USTIC NEUROMA 7 1 years (mean : 53.6)-were eva luated by COP prior to surg ical removal of an acoustic neuroma. Th ey were the first 2 1 patient s to undergo COP afte r the equip ment had been acq uire d by the sen ior author (R.T.S.). Th e test was ordere d for all patients rega rdless of whether or not they had exp resse d any preoperat ive com plaint of dysequ ilibrium . Th e NeuroCom Equ iTest equipment, protocol, and stand ards we re used, and SOT results were analyzed for each patient. At surgery, 20 patient s underwent tum or removal via a transl abyrinthine approach and I (patient 5) via a retrosigmoid (lateral sub occipital) approach . Subjective assessments ofpostop erative balance function wer e obtained via a telephone sur vey conducted no sooner than I year followin g surgery.Th e survey was conducted by the lead author (E.B.), who identified him self as a medic al student working with the seni or author. Patients we re asked to rate their balance function on a scale of 0 to 5: 0: I have no balance problems whatsoev er. I : I feel unstead y while wa lking or standing. 2: I have a spinning sensat ion while wa lking or standing. 3: I fell while standing or walking because I felt off balance. 4: I am afraid to wa lk becaus e I feel off balance. 5: I am whee lchair-bo und because of my balance probl ems.
Results
Preope rativ ely, abnormal COP finding s were noted in 17 of the 21 patients (8 1.0%); SOT conditions 5 and 6 were the most troublesome (table) . We were able to contact 19 of the 21 patients during the postoperative survey ( Of the 3 patients who reporte d that they had experienced a fall , 2 were at least 60 yea rs old and I had had a larger (3 to 4 em) tumor.
Discussion
Blac k et al studied 14 patients who had undergone unil ateral vestibular surgery : 7 labyr inthectomies for Meniere's disease or endol ymph atic hydr ops, 4 middle fossa excisions ofacoustic neuromas, and 3 vestibularnerve sections for Meni ere 's disea se. I Patients were evaluated by COP Volume 84, Number 3 preoperative ly and then at three per iods rang ing from 0 to 9 days, 10 to 99 days, and 100 to 999 days after surgery. Their findings: o Preoperatively, 5 patients (36%) exhibited COP abnormalities during SOT conditio ns 5 and 6. o At 0 to 9 days, all 14 patients ( 100%) exhibited abnor ma lities dur ing cond itions 5 and 6. How ever, at 3 months, 5 of the 24 patients (21%) had abnorm al COPs, inc luding 3 whose preoperative COPs were also abnormal.
This study showed that patients with abnormal preop erative C OPs tended to not maint ain goo d balance function by the late postoperati ve follow-up .
Shepard etal studied 152 patients with vary ing diagn oses who were enrolled in a balance rehabil itation program .' They found that the results of prethera py COP were a reliable indicator of overa ll therapy outco me. Patients whose SOT pattern s indica ted severe vest ibula r dysfunction had significantly poorer posttreatment outco mes (p < 0.05).
Levine et al suggested the poss ibi lity of using preoperat ive COP to determ ine whether aco ustic neurom as sma ller than 1.5 cm origi nate in the inferior or superior branch of the ves tibular nerve.' In a ser ies of 6 patients, they found that at a sway -re ference gai n of 1.5, patients whose neurom as originated in the inferi or branch exhibited abnormalities durin g SOT conditions 5 and 6, whereas patients whose tum ors originated in the superior branch had norm al COPs.
In our study, 81.0% of pati ents with acoustic neuromas it may not reflect acc urately postoperative balance function. Additio nal research aimed at coll ectin g subjective and objective data from larger samples of patients should be helpful in clari fying the value of preoperative COP in this important patient popul ation. had abnorma l preoperat ive COPs , most during SOT con - Table. Patient characteristics and pre-and postoperative results ditions 5 and 6. SOT conditions 5 and 6 force pat ients to rely on vestibu lar input s for balance, even as these inputs are being compromised by the presence of their tumor. We found no correlatio n between the presence or severity of preoperative COP abnormalities and pos toperative balance functio n . Furthermore , we found no correlation between · a patient's age or tumor size and postoperative balance function. The overwhelming maj ority of our patients scored 0 or I on the postoperative survey, indicating that most patients achieve and mai nta in adequate bal an ce function postoperative ly.
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These observations are consis te nt w ith the find ings of EI-Kashlan et ai, who used a survey to correlate preoperative symptoms with postoperative subjective balance func tion in 220 patients who had undergone CDP = computerized dynamic posturography; SOT = sensory organization test ; L = left; NIA = not a vailsurgical resec tion for acoustic ab le; R = right ; WNL = lI' ithin normal limits. neuromas.' They used a dizziness handi cap inve ntory (DHI) sca led from 0 to 100, with 100 ind icating the poorest ba lance function. The postoperative DHl s in their pat ients ranged from 0 to 82 (mean: 17), indicati ng that most patients had adequate balance func tion.
EI-Kash lan et al also found significant correlatio ns between pos to perative balan ce functi on and several preoperative fac tors , including the magnitude of calor ic weak ness on the side of the acoustic neurom a, preoperative vestibular disability scores, abnorma lpositional nystagmu s, abnorma l ves tibuloocularreflex asymmetry on rotary chair testing, and the use ofpostopera tive ves tibu lar habitu ation exercises.' On the other hand, they found no correlation between preo pera tive SOT results durin g COP and vario us postoperative balance outcome measures.
We conc lude that although COP has prove n to be useful for many aspects ofbalance eva luation, it does not app earto be a valuab le prognostic indica tor for predicting subjective postoperative balance function inpatients who are about to undergo surgery for the remova l of an acoust ic neurom a. Although COP prob ably provi des an acc urate reflection of the level ofequilibrium problems exper ienced by patients , Great Efficacy. Great Strawberry Taste.
Halfthe Volume.*

Indications (mild to moderate infections) '
Acute Bacterial Otitis Media and Acute Maxillary Sinusitis (adultsand adolescents) due to H inffuenzoe (including 13l a~as e producingstrains),5pneumonioe (penicill in-susceptible stral .nsonly),and M co~or:hol i s (i ncluding13-lactamase producing strains).Use of cefdinirInthe treatment of acute maxillary sinusitis in pediatric patients is supported by evidence from adequate and well-controlled studies in adults and adolescents.
Pharyngitisrronsillitis due to 5 pyogenes.Cefdinir is effective in the eradication of 5 pyogenes fromthe oropharynx Cefdinir has not, however. been studied for the prevention of rheumatic fever following 5 pyogenes pharyngitisltonsillitis. Only intramuscularpenicillin has been demonstrated to be effective for the prevention of rheumatic fever.
Uncomplicated Skin and Skin Structure Infectionsdue to 5 oureus (including 13-lactamase producing strains) and 5 pyogenes. Importan t Safety Information I •To reducethe devel opment of drug-resistant bacteriaand maintain the effectiveness of OMNICEFand otherantibacterial drugs, OMNICEFshould be used onl y to treat or prevent infections that are proven or strongl y suspected to be caused by bacteria • OMNICEF is contraindicated in patients with known allergy to the cephalosporin class of ant ibiotics • Forpatients with previous hypersensitivity reaction to penicillins,caut ion should be exercised because cross-hypersensitivity among13-lactam antibiotics has been clearlydocumented. If an allergic reaction to cefdinir occurs, the drug should be discontinued • Safety and efficacy in neonates and infants lessthan 6 months of age have not been established · 2% of 2,289 pediatric patients discontinued medication due to adverse events in US and ex-US cl inical trial s. Ps eudom embranou s coliti s has been report ed with nearly all antibacterial agents, includingce fdinir, and may range inseveritytrom mild-to life-threatening. Therefore, it is Important to considerthi s diagnosis in pa tients who present with diarrhea subsequent to the administralion ot antibacterial agents. Tr eatment wit hant ibacterial agentsalters the normal floraofthe colonand may permit overgrowth ot clostridi a. Studies indicate that a toxin produced by Clostridium difficile is a primary cause of "antibioticassociated colitis." Atter thedi agnosis ot pseudomembranous colitis has been established, appropriate therapeutic measures should be ini tiated. Mild cases of pseudomembranous colitis usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management wi th ffuids and electrolytes, protein supplementation, and treatment withan antibacterial drugclin icallyeffective against Clostridium difliei/e. PRECAUTIONS General Prescribing OMN ICEFin the absence of a proven or strongly suspected bacterial infectionoraprophylacticindication isunlikelytoprovide benefit tothepat ientandincreases therisk ofthe development ofdrug-resistant bacteria. As wi thother broad-spectrum antibiotics, prolonged treatment mayresu lt inthe possible emergence and ove r grov~h of resistant organis ms. Careful observation of the patient is essential. If superinfection occurs during therapy, approp riate alternative therapy shoul d be administered. .Cefdinir, as withother broad -spectrum antimicrobials (antibiotics), should be prescribed with cautioninindividuals withahi storyofcolitis. In patients wi th transient or persi stent renai insufficiency (creatini ne clearance <30 mUmin), the total dail y dose of OMNICEF should be reduced because high andprol onged plasma concentrations of cefdinir canresult foll owing recommendeddoses. Information forPalients Patients shouldbe co unseled that antibacterial drugsincluding OMNICEF should only be used to treat bacterial infections. They donottreat viral infections (e.g., the com mon cold). When OMN ICEFisprescribed totreat abacterial infection, patientsshould be told that al though it iscom mon to feel better early inthecourse of therapy, the medication should be taken exacttyasdirected. Skipping doses or not completing the full course of therapy may (I) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and W ill not be treatablebyOMNICEF or other antibacterial drugs inthefuture. Antacids contai ning magnesium or aluminum intertere with the absorption of cefdinir. If thistype ofantacid is required during OMNICEF therapy, OMNICEFshould be taken at least 2 hours beforeor after the antacid. Ironsupplements, includingmultivitaminsthat contain iron, int erferewith the absorpt ion of cefdinir. If iron supplements are requi red during OMNICEF therapy, OMNI CEF should be taken at least 2 hours beforeor after the supplement Iron-fortified infant formula does not significantly interfere wit h the absorption of cefdin ir. Therefore, OMNICEFfor Oral Suspension can be administered withiron-fort ified infant formula. Diabeticpatients andcaregi vers should be awarethat the oral suspension co ntains2.86g of sucrose perteaspoon. Drug Interactions Antacids: (aluminum-or magnesium-containi ng): Concomitant administration of 300-mg cefdini r capsules with30 mL Maalox" TCsuspension reduces the rate (Cm ,,) and extent (AUC) ofabsorption byapproximately 40%. Time to reach Cm " is also prolonged by 1 hour. There are no signiticant effects on cefdinir pharmacokinetics if the antacid is administered 2 hours before or 2 hours after cefdini r. If antacids are required during OMN ICEF therapy, OMNICEF should be taken at least 2 hours beforeor aftertheantacid. Prob en ecid: As with other p-Iactam antibiotics, probenecid inhibits the renal excretionof cefdi nir , resulting inanapproximate doubling inAUC, a 54% Increasein peak cefdinir plasma levels, and a 50%prolongation in theapparent elimination t,/,. Iron Supplements and Foods Fortified With Iron: Concomitant administration of cefdinir with a the rapeutic iron supplement containing 60 mg ofelemental iron (as FeSO,) orvitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%. respectively. If iron supplements are required during OMNICEF therapy, OMNICEFshould be taken atleast 2 hoursbefore or after thesupplement The effect of foods highly fortified with elemental iron (primarily ironfortifiedbreakfast cereals)oncefdinir absorption has not been studied. Concomitantly administered iron-fort ified infant formul a (2.2 mg elemental iron/6 oz) has no significant effect on cefdinir pharmacokinetics. Therefore, OMNICEFfor Oral Suspension can be administered with iron-fortified infant formula. Therehave been reportsofreddish stoolsinpatients receivingcefdinir. In many cases, patients were also receiving iron-containing products. The reddish color isdue totheformation ofanonabsorbable complex between cefdinir oritsbreakdown products and iron inthegastrointestinal tract Drug/Lab oratory TestInteraction s A false-positive reaction tor ketones in the urine may occur with tests using nitroprusside, but not with those using nitroferricyanide. The administration of cefdinir may result in a false-positive reaction for glucose in urine using Clinitest", Benedict's solution. or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as Clinistix" or Tes-Tape") be used. Cephalosporins are known to occasionally induce a positive di rect Coombs' test Carcinogenesis, Mutagenesis, Impairment ofFertitity The carcinogenic potential of cefdinir has not been eval uated. No mutagenic effects were seen in the bacterial reverse mutation assay (Ames) or poi nt mutation assay at the hypoxanthine-guani ne phosphoribosyltransfe rase locus (HGPRT)in V79 Chinese hamster lung cells. No clastogenic effects were observed in vitro in the structural chromosome aberration assay in V79 Chinese hamster lung cells or in vivo in the micronucleus assay in mouse bone marrow. In rats, fertility and reproductive pertormance were notaffected byceldinir atoral doses upto1000mg/kg/day (70 timesthe human dose based on mglkg/day, 11 times based onmg/m 1 /day). Pregnancy -Teratogenic Effects Pregnancy Category B: Cefdinir was not teratogenic in rats atoral doses upto1000mglkg/day (70timesthehumandose based onmglkg/day, 11 times based on mg/m'/day) orin rabbits atoral doses upto10mg/kg/day (0.7 times the human dose based on mglkg/day, 0.23 times based on mg/m'/day). Maternal toxicity (decreased body weight gain) was observed in rabbits at the maximum tolerated dose of 10 mglkg/day withoutadverse effects on offspring. Oecreased body weight occurred in ratfet uses at~100 mg/kg/day, and inrat offspring at~32 mg/kg/day. No effects were observed on maternal reproductive parameters or offspring survival, development, behavior , or reproductivefunction. Thereare, however, no adequate and well-eorurolled studies in preg nant women.Becauseanimal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearlyneeded. Labor and Delivery Cefdinirhas not been studiedforuse during labor and delivery. Nursing Mothers Foll owing administration of si ngle 600-mg doses, celdinir was not detected in humanbreast milk. Pediatric Use Safety andefficacy inneonates and infants lessthan6months ofage have not been established. Useofceldinir forthe treatmentof acutemaxillary sinusilis in pediat ric patients (age 6 months through 12 years) is supported by evidence from adequate and we ll-controlled studies in adults and adolescents, thesimilar pathophysiology ofacute sinusitisin adult and pediatric patients, and comparative pharmacokinetic datainthe pediat ricpopulat ion. Geriatric Use Effi cacy is comparable in geriatric patients and younger adults. While cefdinir has beenwell-tole rated inall age groups, inclinical trialsgeriatric patients experienced a lower rate of adverse events. including diarrhea, thanyounger adults. Oose adjustment inelderlypatientsisnot necessary unless renal functionis marked lycomp romised.
ADVERSE EVENTS Clinical Tri al s -OMNICEF Capsules (Adult and Adofescent Patients):
In clinical trials, 5093 adultand adolescent patients (3841 US and 1252 non-US) we re treated wit h the recommended dose of cefdinir capsules (600 mg/day). Most adve rse events weremi ldand self-limiting. No deaths or permanent disabilities wereattributed to cefdinir. One hundred fortyseven of 5093 (3%) patients discontinued medication due to adverse eventsthought bythe investigators to be possibly, probably, or definitely associated withcefdinir the rapy. Th ediscontinuations were prima rily for gastrointestinal disturbances, usually diarrhea or nausea. Nineteen of 5093 (0.4%) patients werediscontinued due to rash thought related to cefdinir administration. In the US, the foll owing adverse events were thought byinvestigatorsto be possibly, probably, ordefinitely related tocefdinir capsules inmultipl edoseclinical trials (N =3841 cefdini r-treated patients): AOVERSEEVENTSASSOCIA TED WITHCEFDINIR CAPSULES USTRIALSIN ADULT AND ADOLESCENT PATIENTS (N=3841)': Incidence~1% , Diarrhea 15%, Vaginal moniliasis 4%ofwomen, Nausea 3%, Headache2%, Abdom inal pain 1%, Vaginitis 1% of women. Incidence <1% but >0.1%, Rash 0.9%, Oyspepsia 0.7%,Flatulence 0.7%, Vomiting 0.7%, Abnormal stools 0.3%, Ano rexia 0.3%, Constipation 0.3%, Oizziness 0.3%, Ory mouth 0.3%, Asthenia 0.2%, Insomnia 0.2%, Leukorr hea 0.2% of women, Moniliasis 0.2%, Pruritus 0.2%, Somnolence 0.2%, a 1733 males, 2108 females. Thefoll owing laboratoryval ue changes ofpossibleclinical significance, irrespective of rel ationship to ther apy with cefdini r, were seen during clinical trials conducted in the US: LABORATORY VALUE CHANGE S OBSERVEO WITH CEFOINI R CAPSULES US TRIALS IN AOULT AN O ADOLESCENT PATIENTS (N=3841):Incidence~1 % .Tllrine leukocytes 2%, Turi ne protein 2%, iGamma-lg lutamyltransferasea 1%, Llymphocytes. i Lymphocytes 1%, 0.2%, i Microhematuria 1%, Incidence <1% but >0.1% i Glucose' 0.9%, i Urine glucose 0.9%, i White blood cells, l White blood cells 0.9%, 0.7% iA lanine aminotransferase (ALT) 0.7%, iEosinophils 0.7%, i Urine specific qravity, Wrine specific gravity' 0.6%, 0.2%, l Bicarbonate' 0.6%, I Ph osphorus, l Phosphorus' 0.6%, 0.3%, TAspa rtate aminotransfe rase (AST)0.4%, iAlkaline phosphatase 0.3%, i Blood urea nit rogen (BUN) 0.3%, l Hemoglobin 0.3%, i Polymorphonuclear (PMNs), l PMNs 0.3%, 0.2%, i Bilirubin 0.2%, iLactate dehydrogenase' 0.2%, i Platelets 0.2%, i Potassium' 0.2%, i UrinepH' 0.2%, , N<384 1forthese parameters
